Hostname: page-component-5c6d5d7d68-wtssw Total loading time: 0 Render date: 2024-08-19T02:52:31.988Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of cerebral white matter changes on clinical response to cholinesterase inhibitors in dementia

Published online by Cambridge University Press:  16 April 2020

M.E. Devine ,
J.A. Saez Fonseca ,
R.W. Walker ,
T. Sikdar ,
T. Stevens  and
Z. Walker
M.E. Devine
Affiliation:
North East London Mental Health Trust, London, United Kingdom University College London, London, United Kingdom
J.A. Saez Fonseca
Affiliation:
North Essex Mental Health Partnership NHS Trust, Chelmsford, Essex, United Kingdom University College London, London, United Kingdom
R.W. Walker
Affiliation:
Barts and The London NHS Trust, London, United Kingdom
T. Sikdar
Affiliation:
Princess Alexandra Hospital NHS Trust, Harlow, Essex, United Kingdom
T. Stevens
Affiliation:
North Essex Mental Health Partnership NHS Trust, Chelmsford, Essex, United Kingdom
Z. Walker
Affiliation:
North Essex Mental Health Partnership NHS Trust, Chelmsford, Essex, United Kingdom University College London, London, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Cerebral white matter changes (WMC) represent cerebrovascular disease (CVD) and are common in dementia. Cholinesterase inhibitors (ChEIs) are effective in Alzheimer's Disease (AD) with or without CVD, and in Dementia with Lewy Bodies/Parkinson's Disease Dementia (DLB/PDD). Predictors of treatment response are controversial.

Objective:

To investigate the effect of WMC severity on response to ChEIs in dementia.

Method:

CT or MRI brain scans were rated for WMC severity in 243 patients taking ChEIs for dementia. Raters were blind to patients' clinical risk factors, dementia subtype and course of illness. Effects of WMC severity on rates of decline in cognition, function and behaviour were analysed for 140 patients treated for nine months or longer. Analysis was performed for this group as a whole and within diagnostic subgroups AD and DLB/PDD. The main outcome measure was rate of change in Mini Mental State Examination (MMSE) score. Secondary measures were rates of change in scores on the Cambridge Cognitive Examination (CAMCOG), Instrumental Activities of Daily Living (IADL) and Clifton Assessment Procedures for the Elderly – Behaviour Rating Scale (CAPE-BRS).

Results:

There was no significant correlation between severity of WMC and any specified outcome variable for the cohort as a whole or for patients with AD. In patients with DLB/PDD, higher WMC scores were associated with more rapid cognitive decline.

Conclusions:

Increased WMC severity does not predict response to ChEIs in AD, but may weaken response to ChEIs in patients with DLB/PDD.

Type
Poster Session 2: Organic Mental Disorders and Memory and Cognitive Dysfunctions
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S305
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.